PLEASANTON, Calif. - 10x Genomics Inc. (NASDAQ: NASDAQ:TXG), known for its contributions to single cell and spatial biology, announced the release of its new Xenium Prime 5K Pan-Tissue and Pathways panel. This advanced assay is designed to significantly enhance the study of cellular pathways and biomarkers by increasing the plex (the number of simultaneous gene expression measurements) tenfold, while also offering high sensitivity and specificity.
The Xenium Prime 5K assay is touted for its ability to provide comprehensive profiling of cell types, states, and signaling pathways across a variety of tissue and disease types. Its integrated multimodal cell segmentation and industry-leading throughput are expected to facilitate rapid analysis of large tissue areas within a six-day timeframe or less.
Dr. Kevin Wei, M.D., Ph.D., Assistant Professor of Medicine at Harvard Medical School, expressed his enthusiasm for the potential of the new panel, equating its impact to the first time he saw single cell RNA-seq data, emphasizing its ability to explore molecular pathways in human diseases from a single glass slide.
The assay is optimized for both human and mouse research and is customizable, allowing researchers to add up to 100 additional genes tailored to their specific research needs. The development of the panel involved extensive research, including the analysis of RNA-seq data from various organs and tissues, as well as a review of a vast number of peer-reviewed publications.
Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics, highlighted the company's commitment to innovation and customer-centric product development, suggesting that the Xenium Prime 5K assay is a step forward in enabling more biological discoveries.
InvestingPro Insights
In light of 10x Genomics Inc.'s (NASDAQ: TXG) latest innovation, the Xenium Prime 5K Pan-Tissue and Pathways panel, investors may be curious about the financial health and market sentiment surrounding the company. According to InvestingPro data, TXG currently holds a market capitalization of $2.65 billion USD. While the company's revenue has grown by 16.64% over the last twelve months as of Q1 2024, it's important to note that TXG is not currently profitable, with an adjusted P/E ratio of -12.07. This indicates that investors are paying more per share than the company earns, reflecting expectations of future growth or concerns about current profitability.
On the upside, a key InvestingPro Tip highlights that TXG holds more cash than debt on its balance sheet, which is a positive sign of financial stability. Additionally, the company's liquid assets exceed short-term obligations, suggesting that TXG has a solid footing to manage its immediate financial commitments. However, it's worth noting that the stock has experienced significant volatility and has been trading near its 52-week low, which could indicate potential entry points for investors believing in the long-term prospects of the company.
For those interested in further analysis and additional insights, InvestingPro offers a comprehensive list of tips for TXG. There are currently 12 more InvestingPro Tips available, which could help investors make more informed decisions. To access these tips and benefit from the advanced features of InvestingPro, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.